Genentech's MS Drug Receives NICE Approval
Genentech's Ocrevus (ocrelizumab) is now available to UK patients with relapsing remitting MS (RRMS) after the National Institute for Health and Care Excellence (NICE) recommended the drug on Friday (June 22). About 100,000 people in the UK live with MS, and 85% have a relapsing-remitting form eligible for treatment with ocrelizumab. Ocrelizumab has been shown to reduce the number of relapses per year by nearly half and to slow the risk of progression of the disease compared with current treatment. Jo Sopala, Director of Development at the MS Trust welcomed the decision to make the drug routinely available, commenting, “We welcome this positive NICE review for RRMS, and hope that it brings us closer to the treatment being made available to people with early [primary progressive] PPMS too.” Roche/Genentech reports that it is working with NICE to ensure people with early PPMS are also able to access ocrelizumab through the NHS. Click here for Pharm Exec's Brands of the Year report on Ocrevus.
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
Applying Porter’s Five Forces to Portfolio Management in Pharmaceutical R&D: A Strategic Roadmap
March 17th 2025The increasing costs and complexity of R&D in the pharmaceutical industry have necessitated the adoption of strategic portfolio management to optimize resource allocation and enhance competitive advantage.
